NCT05830071View on ClinicalTrials.gov

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
AsthmaChronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

CHF5993

BDP/FF/GB 100/6/12.5 μg pMDI

DRUG

CHF5259

GB 12.5 μg pMDI

DRUG

Moxifloxacin 400mg

400 mg Oral Tablets

DRUG

CHF5993 Placebo

placebo pMDI

Trial Locations (1)

21225

PAREXEL Baltimore Early Phase Clinical Unit, Baltimore

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY